niacinamide has been researched along with Solitary Fibrous Tumors in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Solitary Fibrous Tumors: Rare neoplasms of mesenchymal origin, usually benign, and most commonly involving the PLEURA (see SOLITARY FIBROUS TUMOR, PLEURAL). They also are found in extrapleural sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Malignant solitary fibrous tumors are rare soft-tissue sarcomas." | 6.78 | Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). ( Bompas, E; Chaigneau, L; Chevreau, C; Fournier, C; Isambert, N; Penel, N; Valentin, T, 2013) |
| "Axitinib was marginally active (51%TVI)." | 2.79 | Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. ( Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N, 2014) |
| "Malignant solitary fibrous tumors are rare soft-tissue sarcomas." | 2.78 | Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). ( Bompas, E; Chaigneau, L; Chevreau, C; Fournier, C; Isambert, N; Penel, N; Valentin, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valentin, T | 1 |
| Fournier, C | 1 |
| Penel, N | 1 |
| Bompas, E | 1 |
| Chaigneau, L | 1 |
| Isambert, N | 1 |
| Chevreau, C | 1 |
| Stacchiotti, S | 1 |
| Tortoreto, M | 1 |
| Baldi, GG | 1 |
| Grignani, G | 1 |
| Toss, A | 1 |
| Badalamenti, G | 1 |
| Cominetti, D | 1 |
| Morosi, C | 1 |
| Dei Tos, AP | 1 |
| Festinese, F | 1 |
| Fumagalli, E | 1 |
| Provenzano, S | 1 |
| Gronchi, A | 1 |
| Pennacchioli, E | 1 |
| Negri, T | 1 |
| Dagrada, GP | 1 |
| Spagnuolo, RD | 1 |
| Pilotti, S | 1 |
| Casali, PG | 1 |
| Zaffaroni, N | 1 |
| Domont, J | 1 |
| Massard, C | 1 |
| Lassau, N | 1 |
| Armand, JP | 1 |
| Le Cesne, A | 1 |
| Soria, JC | 1 |
| Le Jeune, S | 1 |
| Des Guetz, G | 1 |
| Bihan, H | 1 |
| Cohen, R | 1 |
| Coindre, JM | 1 |
| Mourad, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Multicenter Stratified Study Evaluating the Efficacy and Toxicity of Sorafenib in Treating Locally Advanced or Metastatic Angiosarcomas That Are Not Accessible to Curative Surgery[NCT00874874] | Phase 2 | 96 participants (Anticipated) | Interventional | 2008-05-31 | Recruiting | ||
| Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients[NCT03023124] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-03-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for niacinamide and Solitary Fibrous Tumors
| Article | Year |
|---|---|
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compo | 2013 |
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compo | 2013 |
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compo | 2013 |
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compo | 2013 |
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humaniz | 2014 |
2 other studies available for niacinamide and Solitary Fibrous Tumors
| Article | Year |
|---|---|
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; | 2010 |
Refractory hypoglycemia controlled by sorafenib in solitary fibrous tumor.
Topics: Adult; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Male; Niacinamide; Phenylurea Compound | 2013 |